Search Results for "Off"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Off. Results 51 to 60 of 283 total matches.
See also: DEET
Inotuzumab Ozogamicin (Besponsa) - An Antibody-Drug Conjugate for ALL (online only)
The Medical Letter on Drugs and Therapeutics • May 21, 2018 (Issue 1547)
on day 1 (0.8
mg/m2), day 8 (0.5 mg/m2), and day 15 (0.5 mg/m2),
followed by 7 days off. For subsequent ...
The FDA has approved inotuzumab ozogamicin
(Besponsa – Pfizer), a humanized anti-CD22
monoclonal antibody conjugated to the cytotoxic
antibiotic calicheamicin, for treatment of relapsed
or refractory B-cell precursor acute lymphoblastic
leukemia (ALL) in adults. It is the first CD22-directed
antibody-drug conjugate to be approved in the US.
Brexpiprazole (Rexulti) for Agitation in Alzheimer's Dementia
The Medical Letter on Drugs and Therapeutics • Jun 26, 2023 (Issue 1679)
treatment of choice has
been off-label use of an antipsychotic drug such
as aripiprazole (Abilify ...
The FDA has approved the oral second-generation
antipsychotic drug brexpiprazole (Rexulti – Otsuka/Lundbeck) for once-daily treatment of agitation associated
with dementia due to Alzheimer's disease (AD).
Brexpiprazole is the first drug to be approved in the US
for this indication. It is also approved for treatment of
schizophrenia and as an adjunct to antidepressants for
treatment of major depressive disorder.
Med Lett Drugs Ther. 2023 Jun 26;65(1679):99-101 doi:10.58347/tml.2023.1679b | Show Introduction Hide Introduction
In Brief: New Warning for Extended-Release Stimulants for ADHD
The Medical Letter on Drugs and Therapeutics • Jul 08, 2025 (Issue 5115)
used off label in these patients. The new warnings were based on an analysis
that found that patients ...
The FDA now requires that the labels of all extendedelease
stimulants used for treatment of attention-deficit/hyperactivity disorder (ADHD) include a warning
about the risks of weight loss and other adverse effects
associated with their use in children <6 years old. The
labels of all stimulants used for treatment of ADHD
already contain a boxed warning about the high risk
of abuse and dependence associated with their use.
Med Lett Drugs Ther. 2025 Jul 8;67(5115):1 doi:10.58347/tml.2025.5115a | Show Introduction Hide Introduction
Omalizumab (Xolair) for Chronic Urticaria
The Medical Letter on Drugs and Therapeutics • May 27, 2013 (Issue 1417)
allergic asthma.1 It has been used off-label for treatment
of allergic rhinitis and food allergies ...
Omalizumab (Xolair) is a recombinant humanized
monoclonal anti-IgE antibody currently approved by
the FDA for treatment of moderate to severe persistent
allergic asthma. It has been used off-label for treatment
of allergic rhinitis and food allergies. Recently the
results of a phase III clinical trial indicated that omalizumab
may be effective in treating chronic urticaria as
well.
Teprotumumab (Tepezza) for Thyroid Eye Disease
The Medical Letter on Drugs and Therapeutics • May 31, 2021 (Issue 1625)
)
have been used off-label to reduce inflammation, but
they are not effective long-term and adverse effects
limit ...
Teprotumumab-trbw (Tepezza - Horizon), an insulin-like
growth factor-1 receptor (IGF-1R) inhibitor, has
been approved by the FDA for IV treatment of thyroid
eye disease. It is the first drug to be approved in the US
for this indication.
In Brief: Hyperthermia with Scopolamine Patches
The Medical Letter on Drugs and Therapeutics • Jun 30, 2025 (Issue 5114)
or recovery
after surgery in adults; it is often used off-label to
reduce drooling in children ...
The FDA has required a new warning in the label for
the scopolamine transdermal patch (Transderm-Scōp, and generics) about a risk of serious or fatal
hyperthermia. Scopolamine, an anticholinergic drug,
is FDA-approved for prevention of nausea and
vomiting associated with motion sickness or recovery
after surgery in adults; it is often used off-label to
reduce drooling in children and adolescents with
neurologic disorders.
Med Lett Drugs Ther. 2025 Jun 30;67(5114):1 doi:10.58347/tml.2025.5114a | Show Introduction Hide Introduction
Drugs for Sexually Transmitted Infections
The Medical Letter on Drugs and Therapeutics • Jun 27, 2022 (Issue 1653)
3 days, then 4 days off,
repeat up to 4x2
Sinecatechins 15% tid up to 16 weeks2,38
MU = million ...
This article includes recommendations for management
of most sexually transmitted infections (STIs)
other than HIV and viral hepatitis. Some of the
indications and dosages recommended here have
not been approved by the FDA (see Table 1).
In Brief: Glycopyrrolate Oral Solution for Sialorrhea
The Medical Letter on Drugs and Therapeutics • Jan 10, 2011 (Issue 1355)
), a synthetic muscarinic
receptor antagonist, has been used off-label for
many years for treatment ...
Glycopyrrolate (Robinul, and others), a synthetic muscarinic receptor antagonist, has been used off-label for many years for treatment of excessive drooling in patients with Parkinson’s disease, in patients taking clozapine for schizophrenia, and in developmentally disabled children.1-3 It has now been approved by the FDA as Cuvposa (Shionogi) for use specifically in children 3-16 years old with severe chronic drooling due to a neurologic condition, such as cerebral palsy. It is being marketed as an oral solution, which will permit more precise weight-based dosing than was possible with the...
Edaravone (Radicava) for ALS
The Medical Letter on Drugs and Therapeutics • Nov 06, 2017 (Issue 1533)
-week cycles. Edaravone should
be administered once daily for 14 days, followed by
14 days off ...
The FDA has approved edaravone (Radicava –
Mitsubishi Tanabe Pharma) for treatment of
amyotrophic lateral sclerosis (ALS). It is the second
drug to be approved in the US for this indication;
riluzole (Rilutek, and generics) was approved in 1995.
Edaravone was approved for treatment of ALS as
Radicut in Japan and South Korea in 2015. It has been
used in Japan and other Asian countries since 2001 for
treatment of acute ischemic stroke.
Oxybutynin for Hot Flashes in Women with Breast Cancer
The Medical Letter on Drugs and Therapeutics • Feb 25, 2019 (Issue 1566)
-controlled
trial suggest that off-label use of the anticholinergic
drug oxybutynin may reduce the frequency ...
Interim results of a double-blind, placebo-controlled
trial suggest that off-label use of the anticholinergic
drug oxybutynin may reduce the frequency and
severity of hot flashes in women with breast cancer.
Extended-release oral oxybutynin (Ditropan XL, and
generics) has been shown to reduce the frequency and
severity of hot flashes in healthy menopausal women.